Regencell Bioscience Holdings Ltd (RGC): R&D Expense
$948.3K
Year ended 2025-06-30
-27.7%
3-year compound annual growth
+19.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $948.3K | -11.1% | 2025-10-31, From 2024-07-01 |
| 2024-06-30 | $1.07M | -32.6% | 2025-10-31, From 2023-07-01 |
| 2023-06-30 | $1.58M | -37.0% | 2025-10-31, From 2022-07-01 |
| 2022-06-30 | $2.51M | +473.1% | 2024-10-25, From 2021-07-01 |
| 2021-06-30 | $438.3K | +13.5% | 2023-10-27, From 2020-07-01 |
| 2020-06-30 | $386.2K | +69.2% | 2022-10-31, From 2019-07-01 |
| 2019-06-30 | $228.2K | n/a | 2021-10-29, From 2018-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Regencell Bioscience Holdings Ltd (RGC) | 2025-06-30 | $948.3K | -11.1% |
| Cyanotech Corp (CYAN) | 2025-03-31 | $449.0K | -34.8% |
| Mannatech Inc (MTEX) | 2025-12-31 | $800.0K | +14.3% |
| Leef Brands Inc. (LEEEF) | 2025-12-31 | $19.7K | +3.8% |
| Adia Nutrition, Inc. (ADIA) | 2025-12-31 | $29.1K | n/a |
| Bon Natural Life Ltd (BON) | 2025-09-30 | $754.2K | -53.5% |
| Niagen Bioscience, Inc. (NAGE) | 2025-12-31 | $6.33M | +5.2% |
| Natural Alternatives International Inc (NAII) | 2025-06-30 | $1.80M | -5.3% |
| Definium Therapeutics, Inc. (DFTX) | 2025-12-31 | $117.67M | +80.2% |
Compare RGC, CYAN, MTEX, LEEEF side by side · Screen every company in Medicinal Chemicals & Botanical Products ↗